Overall Perfomance for "Lion Stock Alerts"
The following three charts can be used by potential investors to gauge the performance of "Lion Stock Alerts":
1 out of 9 campaigns closed down on first day
3 out of 9 campaigns closed up on first day
5 out of 9 campaigns had no net effect
ATNM Promotional Newsletter
The following is a newsletter released by "Lion Stock Alerts" promoting Actinium Pharmaceuticals, Inc.
Don't Want Anymore Emails
Following yesterdays potentially big news, we wanted to briefly update ATNM, our most recent trade opportunity.
As a reminder, yesterday the company announced three potentially major developments.
In its first announcement from yesterday, the company stated
Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting
Here are the highlights
There were no DLTs in first dose cohort, combination advances to additional dose cohorts in RR AML patients
Encouraging initial response observed with subtherapeutic doses of Actimab-A support potential mechanistic synergy with venetoclax
Here are the companys comments from this press release
Dr. Mark Berger, Actinium's Chief Medical Officer, said, We have great excitement for this Actimab-A venetoclax combination trial and its potential for both fit and unfit patients with RR AML. This preliminary first-in-human data is encouraging, particularly the reported patient response after a single cycle of venetoclax with a subtherapeutic dose level of Actimab-A. These initial results support the potential mechanistic synergy of Actimab-A with venetoclax and we are pleased by the progression in the clinic to the next dose level as there were no dose limiting toxicities with this combination.
In the companys second press release from yesterday, they stated
Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting
Here are the highlights
Universal rates of BMT and engraftment continue in Phase 3 SIERRA pivotal trial in relapsedrefractory AML for all patients receiving therapeutic dose of Iomab-B
Second oral presentation to showcase lower rates of sepsis, infections, and mucositis for Iomab-B patients compared to control arm
Here are some of the companys comments from this press release
This is an exciting fourth quarter for the company and we are honored to have multiple oral presentations at this year's ASH conference. Our 3 oral presentations and one poster presentation demonstrate the clinical progress we have seen not only with Iomab-B, but our other programs including Actimab-A in combination with novel and approved therapeutic agents, stated Sandesh Seth, Actinium's Chairman and CEO.
We look forward to presenting the Iomab-B data in further detail during the two oral presentations on the Iomab-B SIERRA study at ASH in December. The company remains on track to report safety and feasibility data from 75% of the patients to be enrolled in SIERRA, as well as to complete the ad hoc interim analysis in the fourth quarter.
In the third press release, the company announced
100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
Here are the highlights
70% of patients achieving remission were MRD-negative with remissions and MRD negativity reported in all dose cohorts
Data to be presented in an oral presentation at the 62nd American Society of Hematology Annual Meeting
As the company further explained
Dr. Mark Berger, Actinium's Chief Medical Officer, commented, We are thrilled with the high rates of remission, MRD negativity and transplant in this trial, which highlights the potential this combination may have for patients with RR AML. Actimab-A targets CD33, which is expressed in virtually all patients with AML, and delivers potent radiation via the alpha-emitting radioisotope Actinium-225.
Actimab-A has produced single-agent response rates as high as 69% in a Phase 2 trial, demonstrating its potential in radiation sensitive blood cancers like AML. While the synergies of radiation with chemotherapy and other modalities is well known, we are highly encouraged that Actimab-A at low doses with CLAG-M produced higher rates of remission and MRD negativity than either agent alone, supporting the synergy of this combination and potential of other Actimab-A combinations.
It's still the case that there is no standard of care for RR AML despite it being a large segment of the AML patient population. Our efforts with our CD33 program are intended to show that Actimab-A, when used together with other synergistic therapeutic modalities, can serve as the backbone of combinations that we hope will be new standards of care for both fit and unfit patients with RR AML. With supporting data also being reported from our Actimab-A venetoclax combination trial we have great enthusiasm of the potential of additional Actimab-A combination with other therapeutic agents, that can treat patients with significant unmet need.
We are continuing to monitor this opportunity.
Sources , , , , , , , , , , , , ,
Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term trade opportunities.
Trading Rules Please Review Before Taking Any Action
Do not invest more than you are willing to lose. No one likes to consider the worst case, but its always a risk that exists. Rule of thumb - if you cannot sleep at night as a consequence of your investment, then you have over invested.
Keep calm. Do not chase. Decide for yourself if you like the trade. If you are not comfortable with the perceived risks, stay out. Timelines are to be decided by you. Approach methodically, and seek technical confirmation for direction. Always trade with a strategy in mind.
Never use market orders. Only use buy and sell limit orders. Protecting your investment is more important than missing gains. Use trailing stop % or trailing stop $ orders. Personally I prefer mental stops while actively managing trades rather than entering your stop into your brokerage account.
Cut losses quickly when dayswing trading. It's better to acknowledge being wrong than to have false hope. Sometimes you will be wrong in doing so, often times it will save you. It all depends on your entry.
Actively manage all your investments trade during market hours only.Trading during prepost market hours carries greater volatilityrisk.
This reportrelease is a commercial advertisement and is for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our services, joining our site or our emailblog list. The track record, gains, upside, andor losses mentioned are all hypothetical and should not be considered as the basis for investment. While we do not charge for the SMS service, standard carrier message and data rates may apply.
This reportrelease is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Reportsreleases distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should read and review, if and to the extent available, any information concerning a marketed company available at the web sites of the U.S. Securities and Exchange Commission the SEC atthe Financial Industry Regulatory Authority the FINRA at and your State Securities Administrator. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at , as well as related information published by the FINRA on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.
You agree and acknowledge that any hyperlinks to the website of 1 an client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in our disseminated reportsreleases is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any company mentioned here.
LionStockAlerts.com is compliant with the Can Spam Act of 2003. LionStockAlerts.com does not offer such advice or analysis, and LionStockAlerts.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.
We have not determined if the statements and opinions of the message are accurate, correct or truthful. The profiles we publish are compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because virtually all information relied upon by us in preparing an Issuer profile comes from a public source which has been made public directly from the Issuer, the information is not confirmed with a second source.
The purpose of this reportrelease, like any promotion, is to provide publicity for the client company, its products or services. Owners and operators of LionStockAlerts.com have been compensated fifteen thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for ATNM by Legends Media on 102920. Owners and operators of LionStockAlerts.com have been compensated twenty five thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for ATNM by Venado Media on 101920. Previously, owners and operators of LionStockAlerts.com have been compensated ten thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for ATNM by Venado Media on 12320. Previously, owners and operators of LionStockAlerts.com have been compensated fifteen thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for ATNM by Venado Media on 1320. Previously, owners and operators of LionStockAlerts.com have been compensated thirty five thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for ATNM by Sunrise Media on 4517. Previously, owners and operators of LionStockAlerts.com have been compensated thirty thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for ATNM by Third Coast Media on 73115. Previously, owners and operators of LionStockAlerts.com have been compensated thirty thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for ATNM by Small Cap Specialist on 6115. Owners and operators of LionStockAlerts.com hold no stocks or bonds in mentioned companies as of 11520. You should not rely on the information presented you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment.
The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions quote may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
Our records indicate that . requested and confirmed to be added to LionStockAlerts.com on July 23, 2019.
6020 Bent Pine Drive
Orlando FL 32828